Table 1.
Characteristics of the cohort.
| AD-MCI patients (N = 62) | AD dementia patients (N = 237) | Cognitively unimpaired (N = 113) | p | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age [mean (SD)] | 71.0 (5.4) | 70.1 (6.8) | 72.3 (6.0) | 0.01a |
| Women [n (%)] | 36 (58.1) | 135 (57) | 54 (47.8) | 0.23b |
| Education (mean [SD]) | 13.0 (4.0) | 11.7 (3.5) | 14.1 (3.5) | < 0.001a |
| APOE 4 positive (n [%])** | 39 (68.4) | 156 (74.6) | 41 (38.0) | < 0.001b |
| Cognition | ||||
| MMSE (mean [SD]) | 26.2 (3.2) | 22.5 (4.5) | 29.2 (0.9) | < 0.001c |
| CDT accepted (n [%]) | 61 (82.9) | 105 (46.1) | 108 (95.6) | < 0.001b |
| TMT A ≥ -2 SD (n [%]) | 51 (85.0) | 127 (59.1) | 106 (93.8) | < 0.001b |
| TMT B ≥ -2 SD (n [%]) | 41 (70.7) | 73 (36.3) | 105 (92.9) | < 0.001b |
| CSF biomarkers | ||||
| sTREM2 ng/ml (mean [SD]) | 9.9 (4.5) | 9.5 (4.8) | 8.8 (3.6) | 0.31c |
| Amyloid β42 pg/ml (mean [SD]) | 628.6 (220.3) | 556.6 (168.3) | 705.2 (206.8) | * |
| Total tau pg/ml (mean [SD]) | 572.2 (264.3) | 735.3 (381.6) | 368.7 (149.2) | * |
| Phosphorylated tau pg/ml (mean [SD]) | 91.1 (38.3) | 91.1 (38.3) | 59.5 (20.1) | * |
Bold values are statistically significant (p ≤ 0.05).
MCI mild cognitive impairment, AD Alzheimer's disease, MMSE mini mental state examination, CDT clock drawing test, TMT trail making test A and B.
a = one-way ANOVA, b = Chi square, c = Kruskal–Wallis, * = comparison not possible due to inter-laboratory variability, % = valid percent without missing, ** = missing genotype data in n = 38.